HONG KONG, Feb 18, 2022 - (ACN Newswire) - Global pandemic control is still facing enormous challenges after more than two years since the outbreak of the COVID-19. Following the Delta and Beta variants, Omicron variant emerged at the end of 2021, and its enhanced infectivity has cast a shadow over the global COVID-19 control. Recently, Omicron quickly spread in Japan and South Korea, and the number of newly confirmed cases in South Korea has exceeded 90,000 for two consecutive days. Although COVID-19 vaccine booster shots have been administered across the globe since 3Q2021, vaccine efficacy is shown to vary among vaccine products, and it is crucial to find and apply a vaccine with stronger protection against Omicron.

Livzon Pharmaceutical Group Inc. ("Livzon"), a long-established pharmaceutical company dedicated to research and development of innovative product, has developed a recombinant protein COVID-19 vaccine (the "V-01 vaccine") leveraging their recombinant protein technology platform since 2021.

It is reported that the V-01 vaccine is a COVID-19 recombinant protein vaccine jointly developed by Livzon MabPharm Inc. ("Livzon MAB") and the Institute of Biophysics, Chinese Academy of Sciences (the "Institute"). To date, Livzon MAB has conducted two global Phase III clinical trials in multiple countries, including (1) two doses of V-01 as basic immunization scheme, and (2) V-01 as a sequential booster for people who have received two doses of inactivated vaccine 3 to 6 months earlier. This is the only global Phase III clinical trial of sequential boosting immunization of the COVID-19 vaccine that have been approved by the regulatory authorities of multiple countries.

On February 16, Livzon has completed the interim analysis of the Phase III clinical trial for the sequential booster protocol, and released key data from this trial. According to the results disclosed, the person-year incidence rates of the V-01 sequential booster (after two doses of inactivated vaccine) group vs. the group who have only received two doses of inactivated vaccine were 6.73% and 12.80%, respectively, which showed a significant statistical difference (P=0.0012); and the absolute vaccine efficacy of the V-01 sequential booster was 61.35%, which is also shown to be significantly superior. The absolute vaccine efficacy after V-01 sequential booster has met World Health Organization's (WHO) standards.

Sixty valid genotype sequencing samples in this trial were confirmed to be Omicron using first-generation genotype sequencing of SARS-CoV-2 virus (the rest of samples are in the process of second-generation sequencing), indicating that V-01 sequential booster can produce good protection against Omicron infection. This is the first COVID-19 vaccine in the world of which the Phase III trial interim results have been disclosed since the Omicron outbreak.

Additionally, the Phase II trial results showed that V-01 had excellent immunogenicity and safety; and the overall incidence of adverse events was lower in the elder group than that of the younger adult group in comparison.
According to the company, the manufacturing of V-01 is well established in China with stable raw material supply and adequate reserves, ready to provide for global market once launched. The production line of Livzon MAB has been approved by the Guangdong Food and Drug Administration, and the vaccine production license has been granted. It is also disclosed that a workshop with an annual bulk product capacity of 3.5 billion doses is up and running at Livzon MAB, and the annual production capacity of formulated product has reached 1.5 billion doses.

With 71.32 million confirmed infected cases and 5.85 million cumulative deaths worldwide, the development and application of a safe and effective COVID-19 vaccine is urgent as the virus is spreading and mutating rapidly. Livzon, as a member of the Chinese Vaccine Research and Development Team, is in the process of obtaining EUA (Emergency Use Authorization) and conditional marketing approval for V-01 vaccine domestically and abroad, so as to provide a more robust and clinical-proven option for continuous immunization boosting for general public and to contribute to the global pandemic control efforts.



Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comGlobal pandemic control is still facing enormous challenges after more than two years since the outbreak of the COVID-19.

How will central banks respond? Inflation and interest rates have been at the forefront of investors’ minds so far this year and that’s unlikely to change for some time yet. Earnings season provided a welcome and timely distraction and enabled markets to find some stability but as we saw towards the end of last week, […]

Stock markets are ending the week in the red after investors were dealt another inflation blow on Thursday which dampened sentiment once more. We were just starting to see confidence building in the markets, with investors seemingly coming to terms with the prospect of four or five rate hikes this year. But the relentless and […]

The pound is slightly lower on Friday, after taking investors on a roller-coaster ride a day earlier. GBP/USD was up over 100 points on Thursday after the US inflation report, but the pound surrendered almost all of these gains later in the day. The UK treated the markets to data dump on Friday, but the […]

Transportation management is a key component of supply chain optimization, especially as global networks become increasingly broad and complex, involving multiple origins, destinations and modes of transport. Today’s transportation management system (TMS) is highly integrated and data-driven to meet challenges head-on and provide greater control and insight across the network - from manufacturers and distributors to shippers and logistics service providers.

Here are some of the key ways the solution has developed to provide greater intelligence and optimization across the multi-party ecosystem, improving flexibility, agility, and resiliency.

ETH eyes $3.5K price level as it managed to reclaim the pre-pandemic support levels and got back above its 50-week exponential moving average as we can see more today in our latest ethereum news. Ethereum’s native token ETH eyes $3.5K level in the upcomign sessions as it reclaimed a historically strong support level at the […]

How aggressively will central banks raise rates? It’s been an incredible couple of weeks in the markets, one in which we’ve seen another hawkish move from multiple central banks, big swings in stocks on the back of earnings, and tensions around Ukraine intensify. The result has been very volatile markets and while the coming week […]

With US Jobs finally showing signs of real recovery, the Fed may be more prepared for a hawkish policy response. 

Oil Crude prices seem to have a one-way ticket to $100 oil.  This week’s rally in crude was supported by the OPEC+ decision to stick to their gradual increase strategy and as US production fell again.  An artic blast is also disrupting some production in Texas and that is driving this latest price surge. Initially […]

It’s been another downbeat session in financial markets, with even US tech stocks losing recovery momentum ahead of the open as focus switches to the January jobs report. While earnings season has overall been something to reflect positively on, there have been plenty of potholes along the way that has continued to stall any recovery […]

The tech rebound is officially over after both Facebook owner’s disastrous earnings and a couple major central bank decisions paved the way for borrowing costs to continue to surge. The ECB’s hawkish shift opens the door for tightening this summer.  The BOE had four dissenters that wanted to double today’s rate increase.  Technology stocks are […]

Inflation has been rising in Canada, with December CPI hitting 4.8% y/y, a 30-year high. The Bank of Canada is keeping a watchful eye on inflation but has a new problem to worry about. With consumer inflation far above wage growth, there are increasing concerns that workers will demand higher wages and salaries in order […]